Compare A O Smith Corp (AOS) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
A O Smith Corp vs Neurocrine Biosciences Inc — how do they compare? A O Smith Corp trades at $60.44 (market cap $8.33B), while Neurocrine Biosciences Inc trades at $175.1 (market cap $17.82B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.1× A O Smith Corp's market cap, and A O Smith Corp pays a 2.35% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AOS | NBIX | |
|---|---|---|
Market Cap | $8.33B | $17.82B |
Sector | Industrials | Health |
52-Week High | $80.47 | $180.55 |
52-Week Low | $55.78 | $123.10 |
Enterprise Value | $8.78B | $16.91B |
Dividend Yield | 2.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
A.O. Smith (AOS) trades at $60.44, up 2.41% today, with a bearish technical signal despite recent leadership changes. The company reported mixed Q1 2026 earnings, missing EPS estimates at $0.85 versus $0.94 expected, while maintaining solid profitability with a 13.84% net margin. Cash flow trends show improving operations, and the stock offers a dividend with a recent $0.36 payout announced.
The outlook is cautious due to earnings volatility and bearish technicals, but valuation appears reasonable with a P/E of 16.12. Risks include China market weakness and competitive pressures, while analyst consensus leans hold with a $68 price target suggesting modest upside potential from current levels.
Neurocrine Biosciences (NBIX) trades at $177.11, down 1.91% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows a bullish technical signal with moving averages supporting upward trends, while RSI levels indicate potential overbought conditions. Recent news highlights strong sales growth from Ingrezza and pipeline advancements, including the Soleno acquisition, reinforcing long-term growth prospects in neuroscience.
Outlook remains positive with a consensus price target of $194, offering ~9.5% upside. Key opportunities include expanding product portfolio and blockbuster drug performance, while risks involve pipeline execution and market volatility. The stock's high valuation multiples require sustained growth to justify current levels, but analyst sentiment is overwhelmingly bullish with 86% buy ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About A O Smith Corp
A.O. Smith Corporation manufactures and markets comprehensive lines of residential and commercial gas, gas tankless, and electric water heaters. Supplementary products include water heating equipment, condensing and noncondensing boilers, and water system tanks. The company's two operating segments are by geographic region: North America (majority of total revenue) and the Rest of the World. A material portion of sales in North America derive from replacing existing products, and the company utilizes a wholesale distribution channel and multiple selling locations. The Rest of the World segment sells primarily to Asian countries and operates sales offices to expand distribution and market its product portfolio.
Read more on AOS →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
